What was the overall market valuation of the US arachnoiditis market in 2024?

The overall market valuation was $499.8 Million in 2024. Read More

What is the projected market valuation for the US arachnoiditis market by 2035?

The projected valuation for 2035 is $835.0 Million. Read More

What is the expected CAGR for the US arachnoiditis market during the forecast period 2025 - 2035?

The expected CAGR during the forecast period 2025 - 2035 is 4.78%. Read More

What segment had the highest valuation in the US arachnoiditis market in 2024?

The Trauma/Surgery Induced segment had the highest valuation at $249.9 Million. Read More

What is the valuation range for the MRI segment in the US arachnoiditis market?

The valuation range for the MRI segment is $200.0 Million to $350.0 Million. Read More

How does the valuation of Pain Medications compare to other treatment segments?

Pain Medications had a valuation range of $149.94 Million to $249.57 Million, indicating a competitive position among treatment options. Read More

What is the valuation range for Adhesive arachnoiditis in the US market?

The valuation range for Adhesive arachnoiditis is $99.96 Million to $167.0 Million. Read More

Which end user segment is projected to have the highest valuation in 2035?

The Hospital and Clinics segment is projected to have the highest valuation, ranging from $249.9 Million to $417.5 Million. Read More

What are the projected valuations for the Chemically Induced segment by 2035?

The projected valuations for the Chemically Induced segment range from $149.9 Million to $250.0 Million. Read More

US Arachnoiditis Market

Q: Which companies are considered key players in the US arachnoiditis market?

Key players include Medtronic, Boston Scientific, AbbVie, Johnson & Johnson, Stryker, NeuroPace, Nuvectra, and Stimwave. Read More

ID: MRFR/HC/14708-HCR

100 Pages

Rahul Gotadki

Last Updated: April 06, 2026

US Arachnoiditis Market Research Report By Type (Adhesive Arachnoiditis, Others), By Cause (Chemically induced, Others), By Diagnosis (Computerized Axial Tomography), By Treatment (Physical Therapy) and By End User (Hospitals & Clinics) - Growth & Industry Forecast 2025 To 2035

US Arachnoiditis Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)4.78%

2024 Market Size$ 499.8 Million

2025 Market Size$ 523.69 Million

2035 Market Size$ 835 Million

Key Players

Medtronic

Boston Scientific

AbbVie

Johnson & Johnson

Stryker

NeuroPace

Trends

Rising Awareness and Education
Advancements in Treatment Options
Collaboration Among Stakeholders

Opportunities

Innovative Research and Development
Increasing Incidence of Arachnoiditis
Regulatory Support and Policy Changes

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Industrial Automation & Equipment, BY Type (USD Million)
  1. 4.1.1 Adhesive arachnoiditis
  2. 4.1.2 Cerebral arachnoiditis
  3. 4.1.3 Arachnoiditis ossificans
  4. 4.1.4 Hereditary arachnoiditis
  5. 4.1.5 Neoplastic arachnoiditis
  6. 4.1.6 Optochiasmatic arachnoiditis
2. 4.2 Industrial Automation & Equipment, BY Cause (USD Million)
  1. 4.2.1 Trauma/Surgery Induced
  2. 4.2.2 Chemically Induced
  3. 4.2.3 Infection-Induced
3. 4.3 Industrial Automation & Equipment, BY Diagnosis (USD Million)
  1. 4.3.1 CAT scan (Computerized Axial Tomography)
  2. 4.3.2 MRI (Magnetic Resonance Imaging)
  3. 4.3.3 Electromyogram (EMG)
4. 4.4 Industrial Automation & Equipment, BY Treatment (USD Million)
  1. 4.4.1 Physical Therapy
  2. 4.4.2 Pain Medications
  3. 4.4.3 Nerve Stimulation
  4. 4.4.4 Psychological Support
5. 4.5 Industrial Automation & Equipment, BY End User (USD Million)
  1. 4.5.1 Hospital and Clinics
  2. 4.5.2 Pharmacies
  3. 4.5.3 Diagnostic Centers
  4. 4.5.4 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Industrial Automation & Equipment
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Industrial Automation & Equipment
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Medtronic (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Boston Scientific (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 AbbVie (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Johnson & Johnson (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Stryker (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 NeuroPace (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Nuvectra (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Stimwave (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE
3. 6.3 US MARKET ANALYSIS BY CAUSE
4. 6.4 US MARKET ANALYSIS BY DIAGNOSIS
5. 6.5 US MARKET ANALYSIS BY TREATMENT
6. 6.6 US MARKET ANALYSIS BY END USER
7. 6.7 KEY BUYING CRITERIA OF INDUSTRIAL AUTOMATION & EQUIPMENT
8. 6.8 RESEARCH PROCESS OF MRFR
9. 6.9 DRO ANALYSIS OF INDUSTRIAL AUTOMATION & EQUIPMENT
10. 6.10 DRIVERS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
11. 6.11 RESTRAINTS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
12. 6.12 SUPPLY / VALUE CHAIN: INDUSTRIAL AUTOMATION & EQUIPMENT
13. 6.13 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TYPE, 2024 (% SHARE)
14. 6.14 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TYPE, 2024 TO 2035 (USD Million)
15. 6.15 INDUSTRIAL AUTOMATION & EQUIPMENT, BY CAUSE, 2024 (% SHARE)
16. 6.16 INDUSTRIAL AUTOMATION & EQUIPMENT, BY CAUSE, 2024 TO 2035 (USD Million)
17. 6.17 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DIAGNOSIS, 2024 (% SHARE)
18. 6.18 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DIAGNOSIS, 2024 TO 2035 (USD Million)
19. 6.19 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TREATMENT, 2024 (% SHARE)
20. 6.20 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TREATMENT, 2024 TO 2035 (USD Million)
21. 6.21 INDUSTRIAL AUTOMATION & EQUIPMENT, BY END USER, 2024 (% SHARE)
22. 6.22 INDUSTRIAL AUTOMATION & EQUIPMENT, BY END USER, 2024 TO 2035 (USD Million)
23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY CAUSE, 2025-2035 (USD Million)
  3. 7.2.3 BY DIAGNOSIS, 2025-2035 (USD Million)
  4. 7.2.4 BY TREATMENT, 2025-2035 (USD Million)
  5. 7.2.5 BY END USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Arachnoiditis Market Segmentation

US Arachnoiditis Market By Type (USD Million, 2025-2035)

Adhesive arachnoiditis
Cerebral arachnoiditis
Arachnoiditis ossificans
Hereditary arachnoiditis
Neoplastic arachnoiditis
Optochiasmatic arachnoiditis

US Arachnoiditis Market By Cause (USD Million, 2025-2035)

Trauma/Surgery Induced
Chemically Induced
Infection-Induced

US Arachnoiditis Market By Diagnosis (USD Million, 2025-2035)

CAT scan (Computerized Axial Tomography)
MRI (Magnetic Resonance Imaging)
Electromyogram (EMG)

US Arachnoiditis Market By Treatment (USD Million, 2025-2035)

Physical Therapy
Pain Medications
Nerve Stimulation
Psychological Support

US Arachnoiditis Market By End User (USD Million, 2025-2035)

Hospital and Clinics
Pharmacies
Diagnostic Centers
Others

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”